Arbet-Engels Christophe has filed 8 insider transactions across 2 companies since August 2023.
Most recent transaction: a grant/award of 450000 shares of Altimmune, Inc. ($ALT) on October 01, 2025.
Activity breakdown: 0 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct. 1, 2025 | Altimmune, Inc. | $ALT | Arbet-Engels Christophe | Chief Medical Officer | A | Stock Options (option to buy) | 450000 | $0.00 | 450,000.0000 | 89,418,028 | 9999.99% | 0.50% |
| Oct. 1, 2025 | Altimmune, Inc. | $ALT | Arbet-Engels Christophe | Chief Medical Officer | A | Restricted Stock Units | 150000 | $0.00 | 150,000.0000 | 89,418,028 | 9999.99% | 0.17% |
| Feb. 12, 2025 | X4 Pharmaceuticals, Inc | $XFOR | Arbet-Engels Christophe | Chief Medical Officer | A | Common Stock | 850000 | $0.00 | 864,207.0000 | 201,062,211 | 5982.97% | 0.42% |
| Jan. 24, 2025 | X4 Pharmaceuticals, Inc | $XFOR | Arbet-Engels Christophe | Chief Medical Officer | S | Common Stock | 11624 | $0.45 | 14,207.0000 | 201,062,211 | 45.00% | 0.01% |
| Jan. 23, 2025 | X4 Pharmaceuticals, Inc | $XFOR | Arbet-Engels Christophe | Chief Medical Officer | A | Common Stock | 25831 | $0.00 | 25,831.0000 | 201,062,211 | 9999.99% | 0.01% |
| Feb. 13, 2024 | X4 Pharmaceuticals, Inc | $XFOR | Arbet-Engels Christophe | Chief Medical Officer | A | Stock Appreciation Right | 180816 | $0.00 | 180,816.0000 | 177,812,480 | 9999.99% | 0.10% |
| Feb. 13, 2024 | X4 Pharmaceuticals, Inc | $XFOR | Arbet-Engels Christophe | Chief Medical Officer | A | Stock Appreciation Right | 475831 | $0.00 | 475,831.0000 | 177,812,480 | 9999.99% | 0.27% |
| Aug. 31, 2023 | X4 Pharmaceuticals, Inc | $XFOR | Arbet-Engels Christophe | Chief Medical Officer | A | Stock Option (right to buy) | 1250000 | $1.28 | 1,250,000.0000 | 63,525,845 | 9999.99% | 1.97% |